Related Experiment Video

Updated: Aug 5, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K

Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing

Thiviyadarshini Rajasegaran1, Chee Wun How2, Anoosha Saud1

  • 1Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia.

Pharmaceuticals (Basel, Switzerland)
|March 29, 2023
PubMed

Insights

Repurposing anti-inflammatory drugs offers a novel strategy for treating non-small cell lung cancer (NSCLC). Delivering these repurposed drugs via inhalation targets the inflammatory pathways driving NSCLC progression.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality.
  • Current treatments for NSCLC often face resistance, leading to advanced stages.
  • Inflammation plays a critical role in NSCLC development and progression.

Purpose of the Study:

  • To explore the repurposing of existing anti-inflammatory drugs for NSCLC treatment.
  • To investigate the potential of targeting the inflammatory tumor microenvironment in NSCLC.
  • To discuss novel drug delivery methods, specifically inhalation, for anti-inflammatory agents in NSCLC.

Main Methods:

  • Review of existing anti-inflammatory drugs for repurposing potential in NSCLC.
  • Analysis of the inflammatory pathways implicated in NSCLC.
  • Evaluation of physico-chemical and nanocarrier properties for inhaled drug delivery.

Main Results:

  • Identified suitable anti-inflammatory drug candidates for NSCLC repurposing.
  • Highlighted the feasibility of targeting inflammation-mediated NSCLC.
  • Discussed the advantages of inhaled drug delivery for NSCLC treatment.

Conclusions:

  • Repurposing anti-inflammatory drugs is a promising strategy for NSCLC management.
  • Inhaled delivery of these agents offers a targeted approach to treat inflammation-driven NSCLC.
  • Further research into drug modification and nanocarriers is essential for optimizing inhaled therapy.
Keywords:
drug deliverydrug-repurposinginflammationinhalationnon-small cell lung cancer

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.1K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
386
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
520
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
233
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.7K